Amatsigroup: Significant Events Of 2015 And Outlook For 2016

• International expansion
• Reinforcement of R&D activities and operational capacities through two acquisitions:
  • SEPS Pharma in Belgium
  • Saint Augustin in France
• 27% expected revenue growth in 2015

TOULOUSE, France--(BUSINESS WIRE)--Amatsigroup, a leading provider of services for the development of human and veterinary pharmaceutical products, announces its outlook for 2016 after a year marked by the group’s international expansion, diversification of its expertise and reinforcement of its production capacities.

International expansion: operations in the United States and Belgium

In late 2014, Amatsigroup opened an operational unit for in-life studies in Terre Haute (Indiana), the heartland of the world’s veterinary industry, with the aim of expanding its services for its US clients. The group then continued its international expansion in 2015 with the acquisition of Belgian company SEPS Pharma.

Recognized for its expertise in formulation development, mainly through its innovative techniques to enhance the bioavailability of low solubility substances and control the release of main active ingredients, SEPS Pharma rounds out Amatsigroup’s services upstream of its pilot and clinical batch manufacturing business.

Reinforcement of R&D activities and production capacities

The acquisition of SEPS Pharma has also increased Amatsigroup’s GMP¹ production capacity for solid dosage forms. In addition, in September 2015, Amatsigroup acquired Pierre Fabre’s pharmaceutical analysis laboratory in Saint-Augustin (Corrèze), driving its growth strategy forward by strengthening its operational capability in analytical support. This acquisition has extended the group’s activities to a new area of expertise – phytotherapy – and will provide a platform for developing transformative partnerships with Pierre Fabre in the field of pharmaceutical analysis services.

2016 growth outlook

Based on strong momentum in 2015, as witnessed by the significant 27% expected growth in revenue to €33 million, Amatsigroup intends to pursue its growth strategy by strengthening its business in the United States and further developing its network of European clients. With a portfolio of more than 300 clients, Amatsigroup intends to consolidate its position as leader in services for the development of human and veterinary pharmaceutical products.

In 2016, Amatsigroup therefore aims to:

• Step up its development activity in the field of biological origin molecules;
• Provide enhanced expertise in analytical and galenic development of plant-based active substances;
• Expand its R&D and analytical support activities;
• Double the capacity of its sterile preclinical and clinical batch production line;
• Increase its clinical batch packaging and labeling capacity to support the distribution of its North American clients’ products in Europe;
• Strengthen its project management services, under the control of Regulatory Affairs, to enhance the complementarity of services offered.

Alain Sainsot, Chairman of Amatsigroup, commented:
“2015 saw the success of our international expansion strategy. The development of our activities in the United States in the heartland of the world’s veterinary industry, and our game-changing acquisition in Belgium have strengthened our relationships with the largest international pharmaceutical groups and biotech companies. In 2016, Amatsigroup intends to consolidate its expertise and leading position in early-stage development and broaden its high-value added service offering to optimize drug development time and cost for its biotech, mid-size or big pharma clients.”

About Amatsigroup:

Amatsigroup, as a CDMO (Contract Development and Manufacturing Organization), provides preclinical and clinical stage services for the development of human and veterinary drugs. Amatsigroup, founded in 2010, was formed through the merger of four companies (Avogadro, Amatsi, DBI, Avepharm) bringing complementary expertise. As of 2014, Amatsigroup began to expand internationally with the acquisition of its Belgian subsidiary SEPS Pharma and US subsidiary Amatsigroup Inc. (Indiana, USA). With more than 240 highly qualified staff and a diversified clientele of 300 international pharmaceutical groups and biotech companies, Amatsigroup is the leading provider of services for the development of veterinary and human pharmaceutical products.

Amatsigroup generated revenue of €26 million in 2014 and contributed to the development and registration of more than 30 drugs for use in human health clinical trials and more than 20 in animal health.

www.amatsigroup.com

¹ GMP: Good Manufacturing Practices

Help employers find you! Check out all the jobs and post your resume.